Lysoway Therapeutics
Valerie Cullen is an accomplished pharmaceutical and biotechnology executive with extensive experience in research and translational science. Currently serving as the Senior Vice President and Head of Research and Translational Science at Lysoway Therapeutics since May 2024, Cullen previously held key leadership roles at Expansion Therapeutics, Generian, Lysosomal Therapeutics Inc, Aldeyra Therapeutics, and Proclara Biosciences, among others. Notable achievements include leading research efforts across multiple sites, overseeing drug development programs, and playing crucial roles in fundraising and scientific strategy. Cullen's educational background boasts a PhD in Pharmacology, extensive postdoctoral training in Neuroscience and Neuropharmacology from prestigious institutions such as Harvard Medical School and King's College London.
This person is not in any teams
This person is not in any offices
Lysoway Therapeutics
Lysoway Therapeutics has developed unique technological approaches to screen and develop potent modulators of lysosomal ion channels, including TRPML1 and TMEM175. These small-molecule compounds can restore autophagic flux and resolution, as well as enhance plasma membrane repair through direct activation of lysosomal exocytosis. These modulators have great potential to treat neurodegenerative diseases with genetic defects in lysosomal function or rare diseases characterized by toxic accumulation of cellular wastes.